It is also possible that the improved hepatic insulin resistance in Tgr5HEP+/+ mice, as compared to Tgr5HEP−/− mice, following treatment with Compound 18 is mediated by reduced inflammation and decreased ectopic triglyceride deposition, characteristic of enhanced liver TGR5 signaling [3,24]. This evidence concerns the gene GPBAR1 and Insulin resistance.